Genetic Analysis of Hemostatic Factors and Cancer

Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention, and Treatment

Volumn , Issue , 2007, Pages 51-63

  Palumbo, Joseph S ^a   Mullins, Eric S ^a   Degen, Jay L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36049004953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420048001-8     Document Type: Chapter

References (81)

1. Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med 2000; 8:679-692.
2. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006; 5(16):1760-1771.
3. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66(22):10643-10646.
4. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996; 56(21):5063-5070.
5. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138(5):1059-1067.
6. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315(26):1650-1659.
7. Brown LF, Van de Water L, Harvey VS, Dvorak HF. Fibrinogen influx and accumulation of crosslinked fibrin in healing wounds and in tumor stroma. Am J Pathol 1988; 130(3):455-465.
8. Dvorak HF, Nagy JA, Berse B, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 1992; 667:101-111.
9. Degen JL, Drew AF, Palumbo JS, et al. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann NY Acad Sci 2001; 936:276-290.
10. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 4(5):932-939.
11. Li WY, Chong SS, Huang EY, Tuan TL. Plasminogen activator/plasmin system: a major player in wound healing? Wound Repair Regen 2003; 11(4):239-47.
12. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131(4):417-430.
13. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3(8):1800-1814.
14. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100(1):27-40.
15. Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A 1997; 94(13):6922-6926.
16. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383(6595):73-75.
17. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 1996; 93(13):6258-6263.
18. Camerer E, Duong DN, Hamilton JR, Coughlin SR. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood 2004; 103(1):152-154.
19. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001; 293(5535):1666-1670.
20. Palumbo JS, Zogg M, Talmage KE, Degen JL, Weiler H, Isermann BH. Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost 2004; 2(8):1368-1379.
21. Sun WY, Witte DP, Degen JL, et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 1998; 95(13):7597-7602.
22. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 1999; 96(15):8663-8668.
23. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999; 82(1):88-92.
24. Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood 2007; 110(1):133-141.
25. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10(5):502-509.
26. Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58(4):213-219.
27. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30(1):95-108.
28. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25(9):489-495.
29. Palumbo JS, Talmage KE, Liu H, La Jeunesse CM, Witte DP, Degen JL. Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood 2003; 102(8):2819-2827.
30. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61(2):711-716.
31. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96(10):3302-3309.
32. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62(23):6966-6972.
33. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105(1):178-185.
34. Sun WY, Coleman MJ, Witte DP, Degen SJ. Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost 2002; 88(6):984-991.
35. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22(2-3):205-222.
36. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93(4):676-681.
37. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93(4):647-654.
38. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4(8):923-928.
39. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152(4):777-784.
40. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60(20):5839-5847.
41. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001; 276(36):33964-33968.
42. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 2001; 8(3):463-470.
43. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996; 87(11):4718-4722.
44. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93(4):631-640.
45. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005; 113(4):525-532.
46. Bugge TH, Lund LR, Kombrinck KK, et al. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16(24):3097-3104.
47. Bugge TH, Kombrinck KW, Xiao Q, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997; 90(11):4522-4531.
48. Curino A, Mitola DJ, Aaronson H, et al. Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. Oncogene 2002; 21(57):8830-8842.
49. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32(suppl 1):61-68.
50. Bromberg ME, Bailly MA, Konigsberg WH. Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb Haemost 2001; 86(5):1210-1214.
51. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995; 92(18):8205-8209.
52. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63(11):2997-3000.
53. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992; 89(24):11832-11836.
54. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factordependent experimental metastasis. J Clin Invest 1998; 101(7):1372-1378.
55. Yu JL, May L, Klement P, Weitz JI, Rak J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004; 30(1):21-30.
56. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140(5):1241-1253.
57. Ott I, Weigand B, Michl R, et al. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005; 111(3):349-355.
58. Luther T, Dittert DD, Kotzsch M, et al. Functional implications of tissue factor localization to cell-cell contacts in myocardium. J Pathol 2000; 192(1):121-130.
59. Sharma L, Melis E, Hickey MJ, et al. The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia. Am J Pathol 2004; 165(1):331-340.
60. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 2004; 15(10):4416-4425.
61. Jiang X, Guo YL, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006; 96(2):196-201.
62. Fischer EG, Riewald M, Huang HY, et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999; 104(9):1213-1221.
63. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease- activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 2000; 97(10):5255-5260.
64. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 2001; 98(14):7742-7747.
65. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104(2):397-401.
66. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003; 90(3):549-554.
67. Trikha M, Zhou Z, Timar J. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62(10):2824-2833.
68. Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res 2000; 6(3):163-174.
69. Isoai A, Ueno Y, Giga-Hama Y, Goto H, Kumagai H. A novel Arg-Gly-Asp containing peptide specific for platelet aggregation and its effect on tumor metastasis: a possible mechanism of RGD peptide-mediated inhibition of tumor metastasis. Cancer Lett 1992; 65(3): 259-264.
70. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited:mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001; 98(6):3352-3357.
71. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92(10):3694-3700.
72. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992; 52(12):3267-3272.
73. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59(6):1295-1300.
74. Yokoyama WM. Natural killer cell immune responses. Immunol Res 2005; 32(1-3):317-325.
75. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88(1):146-157.
76. Allavena P, Bianchi G, Paganin C, Giardina G, Mantovani A. Regulation of adhesion and transendothelial migration of natural killer cells. Nat Immun 1996; 15(2-3):107-116.
77. Curtiss LK, Kubo N, Schiller NK, Boisvert WA. Participation of innate and acquired immunity in atherosclerosis. Immunol Res 2000; 21(2-3):167-176.
78. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol 1995; 155(3):1066-1073.
79. Yakar I, Melamed R, Shakhar G, et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol 2003; 10(4):469-479.
80. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22(10):1944-1948.
81. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23(10):2130-2135.